Mandate

Vinge advises Irisity in connection with a directed new share issue

November 14, 2019 Capital Markets and Public M&A

Vinge is advising Irisity in connection with a directed new share issue of 4,094,000 shares whereby Irisity acquires approximately SEK 35 million.

A subscription price of SEK 8.55 has been determined through an accelerated book building procedure and constitutes a discount of approximately 7.1 per cent in comparison with the closing price of Irisity shares on Nasdaq First North on 13 November 2019. The issue proceeds, which are expected to be sufficient for Irisity to acquire a positive cashflow, are intended to strengthen the company’s financial stability and also be used to expand the organisation within the fields of research, development, marketing, sales and service. The resolution adopted by the board of directors concerning the new share issue is conditional upon the approval thereof at an extraordinary general meeting.

 

Vinge’s team mainly consisted of Anders Strid, Johanna Hamrefält and Lina André.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026